Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000533777 | SCV000639712 | likely benign | Biotin-responsive basal ganglia disease | 2024-01-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002530059 | SCV003692554 | uncertain significance | Inborn genetic diseases | 2021-05-18 | criteria provided, single submitter | clinical testing | The c.1370G>A (p.S457N) alteration is located in exon 6 (coding exon 5) of the SLC19A3 gene. This alteration results from a G to A substitution at nucleotide position 1370, causing the serine (S) at amino acid position 457 to be replaced by an asparagine (N). The p.S457N alteration is predicted to be tolerated by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV003105950 | SCV003761735 | uncertain significance | not provided | 2022-08-15 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Mayo Clinic Laboratories, |
RCV003105950 | SCV004226017 | uncertain significance | not provided | 2023-05-15 | criteria provided, single submitter | clinical testing |